Get started
Author

Domenique D. Zomer-van Ommen

Observed names: D Zomer, D. D. Zomer‐ van Ommen, D. Zomer, D. Zomer-van Ommen, D.D. Zomer, D.D. Zomer-van Ommen, DD Zomer-van Ommen, Domenique D Zomer‐van Ommen, Domenique D. van Ommen, Domenique Zomer, Domenique Zomer-Van Ommen, Domenique Zomer-van Ommen, Zomer (NL) Domenique
ORCID: 0000-0002-1079-6642
Observed ORCID: 0000-0002-1079-6642
OpenAlex ID: A5005986242
Long‐term expanding human airway organoids for disease modeling
2019 · Norman Sachs, Angelos Papaspyropoulos, et al. · The EMBO Journal · 1,123
PDF
An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking
2015 · Kerstin Schneeberger, Georg F. Vogel, et al. · Proceedings of the National Academy of Sciences · 92
PDF
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
2021 · Lutz Naehrlich, Annalisa Orenti, et al. · Journal of Cystic Fibrosis · 61
PDF
Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids
2015 · D.D. Zomer-van Ommen, L.A.W. Vijftigschild, et al. · Journal of Cystic Fibrosis · 61
Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity
2018 · Domenique D. Zomer-van Ommen, Eyleen de Poel, et al. · Journal of Cystic Fibrosis · 55
Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids
2016 · Domenique D. Zomer-van Ommen, Aliaksei V. Pukin, et al. · Journal of Medicinal Chemistry · 52
Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression
2022 · D. Muilwijk, E. de Poel, et al. · European Respiratory Journal · 45
PDF
β 2 -Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis
2016 · Lodewijk A.W. Vijftigschild, Gitte Berkers, et al. · European Respiratory Journal · 39
Epidemiology and management of nontuberculous mycobacterial disease in people with cystic fibrosis, the Netherlands
2022 · Domenique Zomer, Jakko van Ingen, et al. · Journal of Cystic Fibrosis · 17
PDF
Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
2022 · Danya Muilwijk, Domenique D. Zomer-van Ommen, et al. · ERJ Open Research · 16
PDF
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
2024 · Julie Semenchuk, Yumi Naito, et al. · Journal of Cystic Fibrosis · 9
PDF
Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study
2024 · Claire Kim, Mark Higgins, et al. · Journal of Cystic Fibrosis · 9
PDF
Optimization of performance of Dutch newborn screening for cystic fibrosis
2023 · MJ Bouva, JE Dankert-Roelse, et al. · Journal of Cystic Fibrosis · 9
Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis
2023 · Danya Muilwijk, Tessa J. van Paridon, et al. · EClinicalMedicine · 6
PDF
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
2025 · A. M. Zwitserloot, S. Z. Aziz, et al. · Pediatric Pulmonology · 5
PDF
Long-term effectiveness of dual CFTR modulator treatment of Cystic Fibrosis
2022 · D Muilwijk, D Zomer, et al. · European Respiratory Journal · 2
Development and outcomes of a patient driven cystic fibrosis quality of care improvement project
2022 · Jacquelien J. Noordhoek, Joshena Jeyaratnam, et al. · Journal of Cystic Fibrosis · 2
Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry
2026 · Annalisa Orenti, Kris De Boeck, et al. · The Lancet Respiratory Medicine · 1
Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
2026 · Julie Semenchuk, Yumi Naito, et al. · Journal of Cystic Fibrosis · 1
PDF
P067 Real-life data of lumacaftor/ivacaftor therapy in children with cystic fibrosis homozygous for F508del with emphasis on small airway disease in the Netherlands
2023 · A.M. Zwitserloot, S.Z. Aziz, et al. · Journal of Cystic Fibrosis · 1
PDF
P055 Real-world trends in long-term clinical outcomes of lumacaftor/ivacaftor
2020 · D. Muilwijk, D.D. Zomer, et al. · Journal of Cystic Fibrosis · 1
PDF
Registry-based survival trends in cystic fibrosis across Central Europe from 2010 to 2024
2026 · D. Appelt, D.D. Zomer-van Ommen, et al. · Journal of Cystic Fibrosis
Investigating CFTR modulator effectiveness with target trial emulation: lessons from the Dutch CF Registry
2026 · D.D. Zomer-van Ommen, J. Stoelinga, et al. · Journal of Cystic Fibrosis
Benchmarking Dutch cystic fibrosis care: integrating centre metrics with patient-reported experience measures to inform national guidelines
2026 · R. Kos, H.M. Janssens, et al. · Journal of Cystic Fibrosis
Three years of Elexacaftor/tezacaftor/ivacaftor decreases the presence of pathogens in sputum cultures and throat swabs
2025 · Simon Dekker, Bastiaan Bont, et al. · European Respiratory Journal
Works count: 36
Citation count: 1,607
H-index: 10
I10-index: 10
Year
Topic
Type